Giovanni Scambia

Agostino Gemelli University Polyclinic — Italy

Medicine · Health Sciences

117h-index90.2kcitations3.2kworks4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(1143), Endometrial and Cervical Cancer Treatments(874), Uterine Myomas and Treatments(315), Intraperitoneal and Appendiceal Malignancies(279), Endometriosis Research and Treatment(275)

Publications3.2k total

Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer
Drug Resistance Updates·2026Open Access
Minimally Invasive and Intraoperative Ultrasound-Guided Surgery in the Management of Ovarian Cancer Recurrence
2025
Robotic secondary cytoreduction in recurrent ovarian cancer: a tailored approach for kidney transplant recipients
Facts Views and Vision in ObGyn·2025Open Access
Da Vinci Single-Port surgery in an obese woman affected by endometrial cancer
Facts Views and Vision in ObGyn·2025Open Access
Differences in oral health status between cancer patients: a case–control observational study
BMC Oral Health·2025Open Access
Complications and recurrence after pelvic exenteration for gynecologic malignancies: Analysis of surgical complications from the COREPEX study
International Journal of Gynecological Cancer·2025· 1 citedOpen Access
Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy
International Journal of Clinical Oncology·2025Open Access
Validation of the Italian Version of the O’Leary-Sant Questionnaire for Patients with Bladder Pain Syndrome/Interstitial Cystitis
International Urogynecology Journal·2025
Single versus longitudinal scans in the third trimester: a multicenter randomized clinical trial on screening for late-onset intrauterine fetal growth restriction (The RCT on Evaluation of LAte Iugr Screening study)
American Journal of Obstetrics and Gynecology·2025
Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data
International Journal of Gynecological Cancer·2025
Learning from Sparse Point Labels for Dense Carcinosis Localization in Advanced Ovarian Cancer Assessment
Lecture notes in computer science·2025
Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy
ESMO Real World Data and Digital Oncology·2025· 1 citedOpen Access
Complications and Recurrence After Pelvic Exenteration for Gynecologic Malignancies
Obstetrics and Gynecology·2025· 2 citedOpen Access
Effectiveness and safety of an absorbable modified polymer starch powder hemostat versus usual care in gynecology procedures: A prospective, multi-center, and randomized study
PLoS ONE·2025Open Access
Beyond Medical Care: Exploring Socio-Psychological Distress, Violence, and Food Insecurity among Gynecological Patients
Epidemiology Biostatistics and Public Health·2025Open Access
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival and progression-free survival 2 results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Gynecologic Oncology·2025
Long-term survival analysis of a randomized phase II study of front-line chemo-immunothe-rapy with carboplatin-paclitaxel using oreg-ovomab indirect immunization in advanced ovarian cancer (QPT-ORE-002)
International Journal of Gynecological Cancer·2025
Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA nonmutated epithelial ovarian cancer: Results from the randomized phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 study
Gynecologic Oncology·2025· 3 cited
High concordance between immunohistochemistry and next generation sequencing for determining TP53 mutation status in endometrial cancer: A post hoc analysis of the ENGOT-EN5/GOG-3055/SIENDO study
Gynecologic Oncology·2025
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer
ESMO Open·2025· 2 citedOpen Access
page 1 of 159Next →

Frequent Co-authors

Nicoletta Colombo(16), Sandro Pignata(15), Domenica Lorusso(14), Gabriella Ferrandina(13), Susana Banerjee(11), Amit M. Oza(11), Ignace Vergote(10), Philipp Harter(10), Michael Friedländer(9), Anne Floquet(9), Ana Oaknin(8), Isabelle Ray‐Coquard(7), Jonathan A. Ledermann(7), Richard T. Penson(7), Pierluigi Benedetti Panici(7), Stefano Greggi(7), Alla Lisyanskaya(6), Alexandra Léary(6), Gabe S. Sonke(6), Antonio González-Martı́n(6)